Phase II study of the thymidylate synthetase inhibitor CB3717 (N10-propargyl-5,8-dideazafolic acid) in colorectal cancer.

Phase II study of the thymidylate synthetase inhibitor CB3717 (N 10 -propargyl-5,8-dideazafolic acid) in colorectal cancer

• Publication year

  1988

• Venue

  British Journal of Cancer

• Publication date

  1988-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/bjc.1988.143PMID 3408648PMCID 2246458
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargyl-5,8-dideazafolic acid, CB3717.

  1986cited by this paper
• A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.

  1985cited by this paper
• Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.

  1981cited by this paper
• A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

  1981cited by this paper

• Targeting thymidylate synthase by antifolate drugs for the treatment of cancer

  2008cites this paper
• From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates

  2006cites this paper
• TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery

  2004cites this paper
• Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells

  2004cites this paper
• Future directions in the development of pemetrexed.

  2002cites this paper
• Rheumatoid Arthritis and Tumor Necrosis Factor α

  2001cites this paper
• Rheumatoid arthritis and tumor necrosis factor alpha.

  2001cites this paper
• Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis.

  1999cites this paper
• Combined therapeutic efficacy of the thymidylate synthase inhibitor ZD1694 (Tomudex) and the immunotoxin B43(anti-CD19)-PAP in a SCID mouse model of human B-lineage acute lymphoblastic leukemia.

  1998cites this paper
• Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

  1996cites this paper
• Antifolates: current developments.

  1996cites this paper
• Folate-based thymidylate synthase inhibitors as anticancer drugs.

  1995cites this paper
• Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.

  1995cites this paper
• Innovative Antimetabolites in Solid Tumours

  1994cites this paper
• Thymidylate Synthase Inhibitors, Modulation of 5-Fluorouracil and Folate Analogues

  1994cites this paper
• The history of the development and clinical use of CB 3717 and ICI D1694.

  1993cites this paper
• N10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate.

  1992cites this paper
• Oncology drug discovery and clinical trial testing: who's listening?

  1992cites this paper
• The renewed potential for folate antagonists in contemporary cancer chemotherapy.

  1991cites this paper
• Effect of 5-fluorouracil combination therapy on RNA processing in human colonic carcinoma cells.

  1990cites this paper
• The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).

  1988cites this paper
• Toxicities of the antifoliate, CV3717

  1988cites this paper